Baird Rates Faeth Therapeutics (FTH) buy, $57 Price Target
Baird maintains its buy rating on Faeth Therapeutics, setting a $57 price target, a 145.48% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Baird rated Faeth Therapeutics, Inc. ($FTH) "buy" with a $57 price target on June 26, 2026.
Since the rating, $FTH is up 7.1% after 1 week, up 27.9% after 1 month and down 17.8% to date (from the $22.87 close on Jun 26, 2026).
FTH
Faeth Therapeutics, Inc.
Key Points
- Baird reiterated its buy rating on Faeth Therapeutics with a $57 price target on June 26, 2026.
- Baird's $57 price target implies 145.48% upside from Faeth Therapeutics, Inc.'s ($FTH) current $23.22 share price.
- Shares of Faeth Therapeutics traded at $24.67 on Friday, with a 52-week high of $36.76.
- Faeth Therapeutics is a biotechnology company focused on cancer therapeutics, with a market cap of about $636 million.
Get $FTH trade alerts by text
We text you when insiders, Congress or big funds trade $FTH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Faeth Therapeutics, Inc. alert may contain errors. Disclosures
Faeth Therapeutics, Inc. (NasdaqCM: FTH) received a reaffirmation of confidence from Baird, which reiterated its buy rating on the company. Analyst Jack Allen set a price target of $57 for the stock on June 26, 2026. Shares of Faeth Therapeutics traded at $24.67 on Friday.
Baird vs. the S&P 500
Hypothetical returns from Baird's disclosed trades, not real profit or advice. How we model this.
Faeth Therapeutics, Inc. Stock Down 32.7%
Shares of Faeth Therapeutics, Inc. traded near $24.67 on Friday. The company, which operates in the biotechnology industry, has a market capitalization of approximately $636 million. Its stock has experienced a 52-week range from a low of $6.33 to a high of $36.76. The stock's 50-day moving average is $21.65, while the 200-day moving average is $16.72. Faeth Therapeutics has a current ratio of 14.39 and a quick ratio of 14.29, indicating strong liquidity.
$FTH price target
Faeth Therapeutics, Inc. daily closes and this analyst's $57 target. Not advice.
Analysts Set New Price Targets
On June 26, 2026, Baird reiterated its buy rating on Faeth Therapeutics with a $57 price target. This follows an initiation by HC Wainwright & Co. on June 22, 2026, which also gave a buy rating and set a higher target of $60. The consensus among analysts is a strong buy, with a mean target price of $54 based on five analyst opinions.
About Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland. It focuses on discovering and developing therapeutics for cancer patients. The company's pipeline includes PIKTOR, a multi-node inhibitor targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancer, and Solnerstotug, an antibody targeting the immune checkpoint VISTA for solid tumors. Faeth Therapeutics also develops other antibodies for various cancer treatments. The company, originally known as Sensei Biotherapeutics, recently rebranded in June 2026.
Related Filing Alerts
Source: Baird's rating change on $FTH (Jun 26, 2026). Written by software, not financial advice. How we make alerts